TAI-CHING LIAOWang, S.-L., Lee, J.-J., Liao, A.T.S.-L., Lee, J.-J., Liao, A.T.WangJIH-JONG LEESHANG-LIN WANG2019-09-022019-09-022016https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991818980&doi=10.1016%2fj.tvjl.2016.04.013&partnerID=40&md5=31d037772107beab017622d420c18beehttps://scholars.lib.ntu.edu.tw/handle/123456789/417053Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma. Most affected dogs respond during the initial stages of chemotherapy, but many relapse. The aim of this study was to evaluate the relationship between the use of specific chemotherapy drugs and clinical relapse, using the modified Madison-Wisconsin, 25 week chemotherapy protocol. Forty-one of 68 dogs affected with multicentric lymphoma relapsed during the treatment period. Relapse occurred more frequently after the administration of cyclophosphamide (n?=?24; P?<?0.01), compared with vincristine (n?=?9) or doxorubicin (n?=?5). Therefore, the therapeutic outcome of traditional CHOP-based chemotherapy might be improved by replacing cyclophosphamide with other cytotoxic drugs. ? 2016 Elsevier Ltd[SDGs]SDG3cyclophosphamide; doxorubicin; prednisolone; vincristine; antineoplastic agent; cyclophosphamide; doxorubicin; prednisone; vincristine; Article; cancer combination chemotherapy; controlled study; dog; female; lymphoma; male; nonhuman; retrospective study; Taiwan; tumor recurrence; animal; Dog Diseases; lymphoma; recurrent disease; veterinary; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxorubicin; Female; Lymphoma; Male; Prednisone; Recurrence; Vincristinejournal article10.1016/j.tvjl.2016.04.0132-s2.0-84991818980